Clinical Trial Update: Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating dabrafenib plus trametinib given before and after surgery in patients with stage IIIB-C cutaneous melanoma harboring a BRAF …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7 | Phase 2 | Status: ACTIVE_NOT_RECRUITING